GPT Healthcare

Why is GPT Healthcare Ltd falling/rising?

As of 06-Aug, GPT Healthcare Ltd's stock price is currently at 165.10, reflecting a positive trend with a year-to-date increase of 17.72%. However, a significant decline in investor participation raises concerns about sustained interest in the stock.

As of 06-Aug, GPT Healthcare Ltd's stock price is rising, currently at 165.10, reflecting a change of 0.4 (0.24%) upward. The stock has shown a positive performance over the last two days, gaining 1.88% during this period. Additionally, the stock has performed well over the past month, with a return of 4.36%, significantly outpacing the Sensex, which only increased by 0.86% in the same timeframe. Year-to-date, GPT Healthcare Ltd has also demonstrated strong performance with a 17.72% increase, while the Sensex has declined by 7.35%.<BR><BR>Despite these positive indicators, it is important to note that there has been a decline in investor participation, with delivery volume dropping by 62.24% compared to the 5-day average. This could suggest a potential concern regarding sustained interest in the stock. However, the current price is above the 20-day, 50-day, 100-day, and 200-day moving averages, indicating a generally positive trend in the stock's performance. Overall, the recent gains and strong year-to-date performance contribute to the stock's rising price.

Which are the latest news on GPT Healthcare?

Should I buy, sell or hold GPT Healthcare Ltd?

Are GPT Healthcare Ltd latest results good or bad?

GPT Healthcare Ltd's latest results show strong year-on-year growth with a net profit of ₹12.73 crores, up 65.76%, and a revenue increase of 17.82%. However, there is a sequential decline in net profit by 12.63%, indicating potential cost management challenges despite improved operating margins.

GPT Healthcare Ltd's latest results present a mixed picture. On one hand, the company achieved a net profit of ₹12.73 crores for Q1 FY27, which reflects a significant year-on-year growth of 65.76%. Additionally, revenue increased by 17.82% year-on-year to ₹126.20 crores, showcasing the company's ability to attract patient volumes and expand its service offerings.<BR><BR>However, there are concerns regarding the sequential performance. The net profit declined by 12.63% compared to the previous quarter, despite revenues remaining relatively flat, which raises questions about cost management and the sustainability of margins. The operating margin improved to 19.16%, up from 18.49% in Q4 FY26, indicating some operational efficiency, but the decline in net profit suggests challenges in managing expenses.<BR><BR>Overall, while the year-on-year growth figures are strong and indicate a positive trend in revenue generation, the sequential decline in net profit and the need for tighter cost control highlight areas that require attention. Investors should consider these factors when evaluating the company's performance.

When is the next results date for GPT Healthcare Ltd?

The next results date for GPT Healthcare Ltd is 03 August 2026.

The next results date for GPT Healthcare Ltd is scheduled for 03 August 2026.

What does GPT Healthcare do?

GPT Healthcare Ltd is a micro-cap company in the hospital industry, reporting net sales of 126 Cr and a net profit of 15 Cr for March 2026, with a market cap of INR 1,225 Cr. The company has a P/E ratio of 29.00 and a dividend yield of 1.66%.

Overview: <BR>GPT Healthcare Ltd operates in the hospital industry and is categorized as a micro-cap company.<BR><BR>History: <BR>GPT Healthcare Ltd was originally incorporated as "Jibansatya Printing House Private Limited" in 1989. The company changed its name to "GPT Healthcare Private Limited" in 2005 and later converted to a public company, adopting the name "GPT Healthcare Limited" in 2021. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot: <BR>Net Sales: 126 Cr (Quarterly Results - Mar 2026) <BR>Net Profit: 15 Cr (Quarterly Results - Mar 2026) <BR>Market Cap: INR 1,225 Cr (Micro Cap)<BR><BR>Key Metrics: <BR>P/E: 29.00 <BR>Industry P/E: 60 <BR>Dividend Yield: 1.66% <BR>Debt-Equity: 0.25 <BR>Return on Equity: 16.64% <BR>Price to Book: 4.87 <BR><BR>Contact Details: <BR>Details: No Company Details Available <BR>Registrar Address: Not available.

How big is GPT Healthcare?

As of 10th June, GPT Healthcare Ltd has a market capitalization of 1,225.00 Cr, with recent net sales of 472.55 Cr and a net profit of 42.22 Cr. Shareholder's funds are 158.18 Cr, and total assets amount to 319.51 Cr as of March 2022.

As of 10th June, GPT Healthcare Ltd has a market capitalization of 1,225.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, GPT Healthcare reported Net Sales of 472.55 Cr and a Net Profit of 42.22 Cr.<BR><BR>The latest annual period for the balance sheet is March 2022, with Shareholder's Funds amounting to 158.18 Cr and Total Assets of 319.51 Cr.

Who are the peers of the GPT Healthcare?

Peers of GPT Healthcare include Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, Asarfi Hospital, Unihealth Hosp, Chandan Healthcare, and Aprameya Enginee. GPT Healthcare has excellent management and capital structure but below-average growth, with a 1-year return of -3.40%, compared to KMC Speciality's 75.31% and Indrapr.Medical's -9.19%.

Peers: The peers of GPT Healthcare are Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, Asarfi Hospital, Unihealth Hosp, Chandan Healthca, and Aprameya Enginee.<BR><BR>Quality Snapshot: Excellent management risk is observed at GPT Healthcare, while Average management risk is found at Artemis Medicare, Indrapr.Medical, Dr Agarwal's Eye, KMC Speciality, Shalby, Asarfi Hospital, Unihealth Hosp, Chandan Healthca, and the rest. Growth is Excellent at Artemis Medicare, Dr Agarwal's Eye, Unihealth Hosp, and Chandan Healthca, while Good growth is noted at Indrapr.Medical, KMC Speciality, and Asarfi Hospital, and Below Average growth is seen at Shalby and GPT Healthcare. Excellent capital structure is present at GPT Healthcare, Indrapr.Medical, KMC Speciality, and Unihealth Hosp, while Good capital structure is found at Artemis Medicare, Shalby, Asarfi Hospital, and Aprameya Enginee.<BR><BR>Return Snapshot: KMC Speciality has the highest 1-year return at 75.31%, while Indrapr.Medical has the lowest at -9.19%, with GPT Healthcare's 1-year return at -3.40% being higher than Indrapr.Medical's but lower than KMC Speciality's. Additionally, Shalby and Indrapr.Medical have negative six-month returns.

How has been the historical performance of GPT Healthcare?

GPT Healthcare experienced significant growth from March 2021 to March 2022, with net sales increasing to 337.42 Cr from 242.75 Cr, and profit after tax rising to 41.66 Cr from 21.09 Cr, reflecting improved operating margins and cash flow. Total liabilities grew slightly, while shareholder's funds increased, indicating overall financial strength.

Answer:<BR>The historical performance of GPT Healthcare shows significant growth from March 2021 to March 2022.<BR><BR>Breakdown:<BR>In the fiscal year ending March 2022, GPT Healthcare reported net sales of 337.42 Cr, an increase from 242.75 Cr in the previous year. The total operating income also rose to 337.42 Cr from 242.75 Cr. Total expenditure, excluding depreciation, increased to 263.58 Cr from 193.76 Cr, driven by higher raw material costs and employee expenses. Operating profit, excluding other income, improved to 73.84 Cr from 48.99 Cr, leading to an operating profit margin of 21.88%, up from 20.18%. Profit before tax surged to 54.08 Cr from 28.88 Cr, resulting in a profit after tax of 41.66 Cr, compared to 21.09 Cr the previous year, reflecting a PAT margin increase to 12.35% from 8.69%. On the balance sheet, total liabilities grew to 319.51 Cr from 310.61 Cr, while shareholder's funds increased to 158.18 Cr from 133.87 Cr. Cash flow from operating activities rose to 65.00 Cr from 42.00 Cr, contributing to a closing cash and cash equivalent of 8.00 Cr, up from 4.00 Cr. Overall, GPT Healthcare demonstrated robust growth across key financial metrics during this period.

Is GPT Healthcare technically bullish or bearish?

As of November 4, 2025, GPT Healthcare's trend has shifted to a moderate bearish stance, indicated by bearish MACD, Bollinger Bands, and moving averages, along with negative year-to-date and annual returns compared to the Sensex.

As of 4 November 2025, the technical trend for GPT Healthcare has changed from mildly bearish to bearish. The current stance is bearish with a moderate strength. Key indicators driving this include the bearish MACD on the weekly time frame, bearish signals from the Bollinger Bands on both weekly and monthly time frames, and bearish moving averages on the daily time frame. The stock has also shown negative returns year-to-date and over the past year compared to the Sensex, reinforcing the bearish outlook.

Is GPT Healthcare overvalued or undervalued?

As of August 7, 2025, GPT Healthcare is considered very attractive and undervalued, with a PE ratio of 27.73, an EV to EBITDA of 15.96, and a ROCE of 26.05%, making it a compelling investment opportunity despite a year-to-date stock decline of 11.93% compared to the Sensex's 3.18% gain.

As of 7 August 2025, GPT Healthcare's valuation grade has moved from attractive to very attractive, indicating a positive shift in its market perception. The company is currently assessed as undervalued. Key ratios supporting this assessment include a PE ratio of 27.73, an EV to EBITDA of 15.96, and a ROCE of 26.05%. <BR><BR>In comparison with peers, GPT Healthcare's PE ratio is significantly lower than that of Max Healthcare, which stands at 108.4, and Apollo Hospitals at 71.36, highlighting its relative value in the market. Despite recent stock performance showing a decline of 11.93% year-to-date compared to a 3.18% gain in the Sensex, the underlying fundamentals suggest that GPT Healthcare offers a compelling investment opportunity in the hospital industry.

Who are the top shareholders of the GPT Healthcare?

The top shareholders of GPT Healthcare include Gpt Sons Private Limited with 65.57%, mutual funds at 6.65%, foreign institutional investors at 4.48%, and Aditya Birla Sun Life Insurance Company Limited with 3.5%. Individual investors own 15.55%, and there are no pledged promoter holdings.

The top shareholders of GPT Healthcare include Gpt Sons Private Limited, which holds the largest stake at 65.57%. Other significant shareholders are mutual funds, which collectively account for 6.65% of the shares, and foreign institutional investors (FIIs), holding 4.48%. The highest public shareholder is Aditya Birla Sun Life Insurance Company Limited, with a 3.5% stake. Additionally, individual investors own 15.55% of the company. There are no pledged promoter holdings reported.

Has GPT Healthcare declared dividend?

GPT Healthcare Ltd has declared a 10% dividend, amounting to 1 per share, with an ex-date of November 28, 2024. While the company has announced a dividend, total returns have varied, showing a -19.29% return over the last 6 months and an 8.01% return over the past year.

GPT Healthcare Ltd has declared a 10% dividend.<BR><BR>Dividend Details:<BR>- Percentage announced: 10%<BR>- Amount per share: 1 per share<BR>- Ex-date: 28 Nov 2024<BR><BR>Dividend Yield: 1.66%.<BR><BR>Total Returns by Period:<BR>In the last 6 months, the price return was -19.29%, with a dividend return of 0%, resulting in a total return of -19.29%.<BR><BR>Over the past year, the price return was 6.31%, the dividend return was 1.70%, leading to a total return of 8.01%.<BR><BR>For the 2-year period, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 3-year period, the price return and dividend return were both 0%, leading to a total return of 0.0%.<BR><BR>Over the last 4 years, there was no price return or dividend return, resulting in a total return of 0.0%.<BR><BR>In the 5-year period, the price return and dividend return were both 0%, leading to a total return of 0.0%.<BR><BR>Overall, while GPT Healthcare has declared a dividend, the total returns over various periods show mixed performance, with significant losses in the short term and minimal returns in the longer term.